Point72 Asset Management L.P. Acquires 714,461 Shares of Alto Neuroscience, Inc. (NYSE:ANRO)

Point72 Asset Management L.P. increased its position in shares of Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) by 73.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,692,153 shares of the company's stock after acquiring an additional 714,461 shares during the quarter. Point72 Asset Management L.P. owned 6.27% of Alto Neuroscience worth $7,158,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its holdings in shares of Alto Neuroscience by 4.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 844,823 shares of the company's stock valued at $3,575,000 after acquiring an additional 36,319 shares during the period. Marshall Wace LLP acquired a new stake in shares of Alto Neuroscience during the fourth quarter valued at approximately $3,542,000. Northern Trust Corp raised its holdings in shares of Alto Neuroscience by 198.1% during the fourth quarter. Northern Trust Corp now owns 587,135 shares of the company's stock valued at $2,484,000 after acquiring an additional 390,190 shares during the period. Cantor Fitzgerald L. P. acquired a new position in Alto Neuroscience in the 4th quarter valued at approximately $1,575,000. Finally, Integral Health Asset Management LLC acquired a new position in Alto Neuroscience in the 4th quarter valued at approximately $1,269,000.

Alto Neuroscience Stock Up 4.2%

Shares of ANRO traded up $0.12 during mid-day trading on Friday, hitting $3.05. 276,114 shares of the company's stock were exchanged, compared to its average volume of 386,348. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. The firm has a fifty day moving average of $2.35 and a two-hundred day moving average of $3.39. The stock has a market cap of $82.68 million, a price-to-earnings ratio of -1.31 and a beta of 1.87. Alto Neuroscience, Inc. has a twelve month low of $1.60 and a twelve month high of $17.55.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.06. On average, sell-side analysts forecast that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

Analyst Ratings Changes

ANRO has been the topic of several research reports. Wedbush reiterated a "neutral" rating and issued a $4.00 price objective on shares of Alto Neuroscience in a research note on Thursday, May 15th. William Blair reiterated an "outperform" rating on shares of Alto Neuroscience in a research note on Friday, March 21st. Finally, HC Wainwright initiated coverage on shares of Alto Neuroscience in a research note on Monday, April 7th. They issued a "buy" rating and a $10.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $15.40.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.